UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July, 2015
Commission File Number: 001-37368
ADAPTIMMUNE THERAPEUTICS PLC
(Translation of registrant’s name into English)
101 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
|
Form 20-F |
|
x |
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
|
Yes |
|
o |
No o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|
Yes |
|
o |
No o |
Other Events
On July 20, 2015, Adaptimmune Therapeutics plc (the “Company”) issued a press release announcing that data from its phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.
Exhibits
|
99.1 Press release dated July 20, 2015 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Adaptimmune Therapeutics plc | |
|
|
|
|
|
|
By: |
/s/ Margaret Henry |
|
|
Name: |
Margaret Henry |
|
|
Title: |
Corporate Secretary |
|
|
|
|
|
Date: July 20, 2015 |
|
|